# Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Canonical URL: https://biopharmsignal.com/news/AZYO/elutia-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026
Ticker: AZYO
Company: Aziyo Biologics
Source: Aziyo Biologics
Published: 2026-04-30 20:05 EST
Original Source URL: https://investors.elutia.com
## Summary

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026.

## Article Body
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026.
## Recent Company News
- 2026-05-14 20:06 EST — [Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market](https://biopharmsignal.com/news/AZYO/elutia-reports-first-quarter-2026-results-and-highlights-nxt-41x-progress-toward-1-5-billion-u-s-plastic-and-reconstructive-surgery-market) — Source: Aziyo Biologics
- 2026-05-14 20:01 EST — [Elutia to Present at the 16th Annual LD Micro Invitational on May 18th](https://biopharmsignal.com/news/AZYO/elutia-to-present-at-the-16th-annual-ld-micro-invitational-on-may-18th) — Source: Aziyo Biologics
- 2026-04-30 20:05 EST — [Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026](https://biopharmsignal.com/news/AZYO/elutia-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026) — Source: Aziyo Biologics
- 2026-03-17 12:00 EST — [Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19](https://biopharmsignal.com/news/AZYO/elutia-to-present-at-sidoti-s-small-cap-virtual-investor-conference-march-18-19) — Source: Aziyo Biologics
- 2026-03-13 12:00 EST — [Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AZYO/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4) — Source: Aziyo Biologics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)